HDFC Pharma and Healthcare Fund - Growth Option
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 04-10-2023
AUM:
₹ 2,158.58 Cr
Expense Ratio
2.88%
Benchmark
BSE Healthcare Index
ISIN
INF179KC1HL7
Minimum Investment
100.0
Minimum Topup
100.0
Minimum SIP Amount
100
Fund Manager
Mr. Nikhil Mathur
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Growth Option | 19.05 | - | - |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
19.507
Last change
0.13 (0.6664%)
Fund Size (AUM)
₹ 2,158.58 Cr
Performance
28.59% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
Fund Manager
Mr. Nikhil Mathur
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 8.56 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 8.05 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 6.07 |
| GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | 6.06 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.93 |
| ASTER DM HEALTHCARE LIMITED EQ | 5.46 |
| ALKEM LABORATORIES LIMITED EQ | 4.69 |
| ANTHEM BIOSCIENCES PRIVATE LIMITED EQ NEW FV Rs. 2/- | 4.55 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 4.39 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 4.27 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 97.3 |
Peer Comparison
| Scheme Name | 5Y (%) |
|---|---|
| HDFC Pharma and Healthcare Fund Gr | 0.0 |